GlobeNewswire by notified

Intertrust provides Q4 and full year 2021 trading update; transaction with CSC progressing as planned

Share

Amsterdam, the Netherlands – 13 January 2022 – Intertrust N.V. (“Intertrust” or “Company”) [Euronext: INTER], a global leader in providing tech-enabled fund and corporate solutions, today provides a Q4 and full year 2021 trading update. Full year 2021 underlying revenue growth was approximately 1.5% and full year adjusted EBITA margin was approximately 30%. Intertrust confirms that the public offer by CSC is progressing as planned and reference is made to the joint press release issued by CSC and Intertrust on 30 December 2021.

Q4 2021 underlying revenue growth was slightly negative compared to the fourth quarter of 2020, driven by a continued decline in the Netherlands, Luxembourg and Cayman Islands. This was mainly due to lower productivity as a result of elevated employee attrition, which continued through the end of December. Full year 2021 underlying revenue growth was approximately 1.5%, below the Company’s guidance of 2-4% growth. Underlying revenue growth excluding the Netherlands, Luxembourg and Cayman Islands was more than 8% in FY 2021, indicating the competitive strength of the Company’s offering in growth markets.

While expenses were in line with expectations, the lower revenue growth led to an adjusted EBITA margin of approximately 31% for the fourth quarter of 2021 and approximately 30% for the full year 2021. This is slightly below the guidance range of 31-32%. As a result, the leverage ratio is expected to be approximately 3.7x, compared to guidance of ‘below 3.4x’.

The figures provided today are unaudited. Intertrust will publish its full set of audited Q4 and full year 2021 results on 10 February 2022.

This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Verisk Welcomes Olumide Soroye to Its Board of Directors18.8.2022 22:15:00 CEST | Press release

JERSEY CITY, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Verisk (Nasdaq: VRSK) today announced that Olumide Soroye has been appointed independent director of the company’s Board of Directors effective immediately. Soroye brings three decades of leadership experience across multiple industries. “Olumide’s experience in software, data analytics, AI, and growth-minded leadership make him an exceptional addition to Verisk’s board,” Verisk CEO Lee Shavel said. “We look forward to working closely with Olumide to ensure that we continue to drive value and positive impact for all Verisk stakeholders including shareholders, clients, employees and partners.” Soroye, 50, is president and chief executive officer of Fortive Corporation’s Intelligent Operating Solutions segment. Before Fortive, he held leadership roles at CoreLogic, where he was managing director of property intelligence & risk management, and QuinStreet, where he was senior vice president of the company’s technology and home services b

Galapagos receives transparency notification from FMR LLC18.8.2022 22:01:00 CEST | Press release

Mechelen, Belgium;18 August 2022, 22.01CET;regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 15 August 2022 from FMR LLC, who notified that it holds 3,740,842 of Galapagos’ voting rights, consisting of 3,740,842 ordinary shares. FMR LLC controls investment funds FIAM Holdings LLC, Fidelity Management & Research Company LLC, Fidelity Management Trust Company and Strategic Advisers LLC, of which Fidelity Management & Research Company LLC increased its position to 3,303,128 voting rights, and no longer holds any equivalent financial instruments, and Strategic Advisers LLC decreased its position to 10,082 voting rights. FMR LLC's holding of 3,740,842 Galapagos' voting rights represents 5.69% of Galapagos' currently outstanding 65,728,511 shares. FMR LLC thus remains above the 5% threshold of Galapagos’ voting rights considering the

Bavarian Nordic Expands Capacity with U.S. Contract Manufacturer for Filling of Smallpox/Monkeypox Vaccines18.8.2022 20:24:11 CEST | Press release

U.S. FDA approved facility operated by Grand River Aseptic Manufacturing will assist in filling of already manufactured bulk vaccine to expedite deliveries of monkeypox vaccines to the U.S.Agreement will significantly expand Bavarian Nordic’s manufacturing capacity for the benefit of the U.S. and globallyExpedited tech transfer has already started, allowing for manufacturing of first doses in 2022 COPENHAGEN, Denmark, August 18, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has entered into an agreement with Grand River Aseptic Manufacturing (GRAM), a U.S. based contract manufacturer, for fill and finish of JYNNEOS smallpox/monkeypox vaccine. As announced on July 15, 2022, Bavarian Nordic received an additional order for 2.5 million doses the vaccine from the U.S. Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR), which will be filled at GRAM using bulk vaccine already ma

Bavarian Nordic udvider produktionskapaciteten via aftale med amerikansk kontraktproducent om fyldning af koppe-/abekoppevacciner18.8.2022 20:24:11 CEST | pressemeddelelse

Den FDA-godkendte kontraktproducent, Grand River Aseptic Manufacturing, vil bistå med fyldning af allerede produceret råvaccine med henblik på at fremskynde leverancer af abekoppevacciner til USAAftalen vil øge Bavarian Nordics produktionskapacitet markant til gavn for både USA og lamde globaltEn accelereret procesoverførsel er allerede startet, hvilket muliggør produktion af de første doser i 2022 KØBENHAVN, Danmark, 18. august 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabet har indgået en aftale med den amerikanske kontraktproducent Grand River Aseptic Manufacturing (GRAM) om fyldning af JYNNEOS koppe-/abekoppevaccine. Som meddelt den 15. juli 2022, modtog Bavarian Nordic en yderligere ordre på 2,5 mio. doser af vaccinen fra U.S. Biomedical Advanced Research and Development Authority (BARDA), en del af Administration for Strategic Preparedness and Response (ASPR), som vil blive påfyldt på GRAMs facilitet ved brug af den råvaccine, der allerede er fremstillet og fa

PCI Biotech: Company update18.8.2022 18:05:06 CEST | Press release

Oslo (Norway), 18 August 2022 – PCI Biotech (OSE: PCIB), a cancer-focused biopharma company developing innovative therapeutics that address significant unmet medical needs, today announced that the previously reported efforts to finance a planned Ph II trial in head and neck cancer have not under the current market conditions resulted in a feasible way forward. As PCI Biotech will not conduct a company-sponsored Ph II trial with the fimaVacc technology a reduction of the clinical team will be enacted during the second half of 2022. Further details about the development plans for the non-clinical assets will be given at the upcoming Q2 reporting, scheduled 31st August 2022. The cash position per Q2 2022 is around NOK 76 million and the financial runway is estimated to be towards the end of 2023. Contact information: Ronny Skuggedal, Interim CEO rs@pcibiotech.no Mobile: +47 9400 5757 About PCI Biotech PCI Biotech is a biopharmaceutical company focusing on development and commercialisatio